Evidence map›Paper›PMID 35714101›Full record

ArticlePloS one2022

The fading impact of lockdowns: A data analysis of the effectiveness of Covid-19 travel restrictions during different pandemic phases.

Barry Smyth

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Barry SmythInsight SFI Research Centre for Data Analytics, School of Computer Science, University College Dublin, Dublin, Ireland.ORCID 0000-0003-0962-3362

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As countries struggled with SARS-COV2 outbreaks at the beginning of 2021, many citizens found themselves in yet another period of increasing travel restrictions, if not a strict lockdown. At the same time there was concern that further restrictions would prove to be less effective due to a range of reasons including increasing pandemic fatigue or the lack of appropriate supports. In this study we investigate whether restrictions remained effective as a way to limit non-essential travel in order to curb virus transmission. We do this by analysing adherence during periods of increasing and decreasing restrictions in 125 countries during three different 4-month phases, early (March-June 2020), middle (July-October 2020), and late (November 2020-February 2021) over the course of the first year of the pandemic, and prior to significant population-wide vaccination. We use the strength of the relationship between restriction levels and the level of personal mobility associated with non-essential travel in order to determine the degree of adherence to the restrictions imposed. We show that there is evidence of a significant decrease in adherence to restrictions during the middle and late phases of the pandemic, compared with the early phase. Our analysis further suggests that this decrease in adherence is due to changes in mobility rather than changes in restrictions. We conclude, therefore, that restrictions have become less effective at curbing non-essential travel, which may alter the cost-benefit analysis of restrictions and lockdowns, thus highlighting the need for governments to reconsider large-scale restrictions as a containment strategy in the future, in favour of more focused or flexible mitigation approaches.

Indexed as

COVID-19PandemicsCommunicable Disease ControlData AnalysisHumansRNA, ViralSARS-CoV-2TravelRNA, Viral

Identifiers

PMID35714101
PMCPMC9205480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.